Kasturi Das
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kasturi Das has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Karen Chau
Department of Pathology and Laboratory Medicine North Shore University Hospital and Long Island Jewish Medical Center, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health New Hyde Park New York USA
6 shared publications- Deepika Savant
Hofstra Northwell School of Medicine
5 shared publications - Amr Ali
Department of Pathology and Laboratory Medicine North Shore University Hospital and Long Island Jewish Medical Center, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health New Hyde Park New York USA
4 shared publications Cecilia Gimenez
Department of Pathology and Laboratory Medicine, Northwell Health Donald and Barbara Zucker School of Medicine at Hofstra Greenvale New York USA
4 shared publicationsPriyanka Karam
Department of Pathology and Laboratory Medicine North Shore University Hospital and Long Island Jewish Medical Center, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health Hempstead New York USA
4 shared publications- Seema Khutti
Department of Pathology and Laboratory Medicine North Shore University Hospital and Long Island Jewish Medical Center, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health Hempstead New York USA
4 shared publications
Latest Publications
- 11 March 2026
- Published by Wiley in Diagnostic Cytopathology
- Vol. 54 (6) , 436-443
Classifying Liver Cytology Using the WHO Reporting System: Institutional Experience and Malignancy Risk Assessment
Aim: The World Health Organization's (WHO) Reporting System for Liver Cytopathology aims to standardize communication with clinicians globally to improve patient management. Our study reclassifies liver cytology reports based on the WHO classification and assesses the risk of malignancy (ROM) in each category. Methods: Liver cytology reports from 2019 to 2023 were retrieved to obtain demographic details, clinical data, cytology, and surgical follow‐up (SFU). Cytology diagnoses were reclassified using the WHO classification. ROM was analyzed based on SFU. Results: Our study had 976 cases, age ranged from 1–96 years, with an average age of 67 years. Male: female ratio was 1:1. Majority of lesions (400/525, 76%) were less than 5 cm. Location of the lesion was available in 595 cases, with right lobe being the most common (64%; n = 383), followed by left lobe (36%, n = 212). 883 cases (90%) underwent rapid onsite evaluation. Reclassification using the WHO classification system into 5 categories included non‐diagnostic ( n = 79), benign ( n = 117), atypical ( n = 25), suspicious for malignancy ( n = 6) and malignant ( n = 749). Thirty‐one cases (3%) had cytology follow up, 71(7.3%) had SFU. The ROM in the SFU cohort was 17% (1/6; 95% CI: 10%–76%) in non‐diagnostic, 23% (3/13, 95% CI: 15.4%–30.6%) in benign and 100% in atypical (3/3, 95% CI: 88%–100%), suspicious for malignancy (2/2, 95% CI: 50%–100%) and malignant(47/47, 95% CI: 99.5%–100%) categories. Repeat FNA yielded malignant upgrade rates of 80% (4 out of 5) in non‐diagnostic and 75% (3 out of 4) in atypical categories. Conclusion: We present the values of ROM in the various categories of the WHO Reporting System for Liver Cytopathology using a large cohort of cases. Repeat sampling is recommended in non‐diagnostic and atypical categories based on an increase in malignant upgrades in these categories.
- 11 March 2026
- Published by Wiley in Diagnostic Cytopathology
- Vol. 54 (6) , 436-443
Classifying Liver Cytology Using the WHO Reporting System: Institutional Experience and Malignancy Risk Assessment
Aim: The World Health Organization's (WHO) Reporting System for Liver Cytopathology aims to standardize communication with clinicians globally to improve patient management. Our study reclassifies liver cytology reports based on the WHO classification and assesses the risk of malignancy (ROM) in each category. Methods: Liver cytology reports from 2019 to 2023 were retrieved to obtain demographic details, clinical data, cytology, and surgical follow‐up (SFU). Cytology diagnoses were reclassified using the WHO classification. ROM was analyzed based on SFU. Results: Our study had 976 cases, age ranged from 1–96 years, with an average age of 67 years. Male: female ratio was 1:1. Majority of lesions (400/525, 76%) were less than 5 cm. Location of the lesion was available in 595 cases, with right lobe being the most common (64%; n = 383), followed by left lobe (36%, n = 212). 883 cases (90%) underwent rapid onsite evaluation. Reclassification using the WHO classification system into 5 categories included non‐diagnostic ( n = 79), benign ( n = 117), atypical ( n = 25), suspicious for malignancy ( n = 6) and malignant ( n = 749). Thirty‐one cases (3%) had cytology follow up, 71(7.3%) had SFU. The ROM in the SFU cohort was 17% (1/6; 95% CI: 10%–76%) in non‐diagnostic, 23% (3/13, 95% CI: 15.4%–30.6%) in benign and 100% in atypical (3/3, 95% CI: 88%–100%), suspicious for malignancy (2/2, 95% CI: 50%–100%) and malignant(47/47, 95% CI: 99.5%–100%) categories. Repeat FNA yielded malignant upgrade rates of 80% (4 out of 5) in non‐diagnostic and 75% (3 out of 4) in atypical categories. Conclusion: We present the values of ROM in the various categories of the WHO Reporting System for Liver Cytopathology using a large cohort of cases. Repeat sampling is recommended in non‐diagnostic and atypical categories based on an increase in malignant upgrades in these categories.
- 17 November 2025
- Published by Wiley in Diagnostic Cytopathology
- Vol. 54 (2)
Metastatic Vulvar Paget's Disease Presenting in a Supraclavicular Lymph Node: A Diagnostic Challenge on Fine Needle Aspiration Cytology
Background: Extramammary Paget's disease (EMPD) of the vulva is a rare intraepithelial adenocarcinoma with a typically indolent course. Distant metastasis, particularly to supradiaphragmatic lymph nodes, is exceedingly uncommon and poses a significant diagnostic challenge. Case Presentation: We report a rare case of metastatic vulvar EMPD presenting as a left supraclavicular lymph node enlargement in a 72‐year‐old woman with a known history of EMPD since 2014. Cytologic smears from the lymph node revealed large, discohesive epithelial cells with pale vacuolated cytoplasm and prominent nucleoli. The concurrent core biopsy demonstrated effacement of nodal architecture by similar cells forming loose clusters and abortive glandular structures. Immunohistochemistry showed tumor cells positive for CK7, CK20, GATA3, and TRPS‐1, with focal mammaglobin expression and negative staining for CDX2, PAX8, CK5/6, P40, and P63. Special stain with mucicarmine highlighted abundant intracytoplasmic mucin—a key morphologic clue favoring EMPD over a breast primary. Conclusion: This case illustrates the diagnostic complexity of EMPD metastasizing to an unusual site and highlights the critical role of cytomorphology, special stains, and immunohistochemistry in excluding alternate primaries. Mucicarmine staining highlighted abundant intracytoplasmic mucin, serving as a useful adjunct in raising suspicion for EMPD. While not specific, in conjunction with cytomorphology and immunohistochemistry, this supported EMPD over invasive ductal carcinoma of the breast. Given the rarity of such distant nodal metastases, a high index of suspicion should be maintained for EMPD in patients with a known history, even when metastases appear in non‐regional lymph nodes.
- 17 November 2025
- Published by Wiley in Diagnostic Cytopathology
- Vol. 54 (2)
Metastatic Vulvar Paget's Disease Presenting in a Supraclavicular Lymph Node: A Diagnostic Challenge on Fine Needle Aspiration Cytology
Background: Extramammary Paget's disease (EMPD) of the vulva is a rare intraepithelial adenocarcinoma with a typically indolent course. Distant metastasis, particularly to supradiaphragmatic lymph nodes, is exceedingly uncommon and poses a significant diagnostic challenge. Case Presentation: We report a rare case of metastatic vulvar EMPD presenting as a left supraclavicular lymph node enlargement in a 72‐year‐old woman with a known history of EMPD since 2014. Cytologic smears from the lymph node revealed large, discohesive epithelial cells with pale vacuolated cytoplasm and prominent nucleoli. The concurrent core biopsy demonstrated effacement of nodal architecture by similar cells forming loose clusters and abortive glandular structures. Immunohistochemistry showed tumor cells positive for CK7, CK20, GATA3, and TRPS‐1, with focal mammaglobin expression and negative staining for CDX2, PAX8, CK5/6, P40, and P63. Special stain with mucicarmine highlighted abundant intracytoplasmic mucin—a key morphologic clue favoring EMPD over a breast primary. Conclusion: This case illustrates the diagnostic complexity of EMPD metastasizing to an unusual site and highlights the critical role of cytomorphology, special stains, and immunohistochemistry in excluding alternate primaries. Mucicarmine staining highlighted abundant intracytoplasmic mucin, serving as a useful adjunct in raising suspicion for EMPD. While not specific, in conjunction with cytomorphology and immunohistochemistry, this supported EMPD over invasive ductal carcinoma of the breast. Given the rarity of such distant nodal metastases, a high index of suspicion should be maintained for EMPD in patients with a known history, even when metastases appear in non‐regional lymph nodes.
- 7 December 2024
- Published by Wiley in Diagnostic Cytopathology
- Vol. 53 (3) , 121-126
TRPS1 Immunohistochemistry in Salivary Gland Neoplasms: Analysis on Cytology Cell Blocks and Surgical Follow‐Up Correlation
Introduction: In this study we aim to analyze the TRPS1 immunostaining of salivary gland tumors (SGT) on cytology cell blocks and compare the staining pattern on subsequent surgical resections.Methods: Malignant SGTs, oncocytomas and basal cell adenomas diagnosed on fine needle aspiration were retrieved from 2019 to 2021 database. Cases with surgical follow‐up were selected. TRPS1 staining was performed on cytology cell blocks and surgical specimens. Scoring was interpreted by two pathologists independently.Results: Our cohort comprised of 58 cases: 45 malignant and 13 benign. TRPS1 scoring was interpreted for 44 cytology and 51 surgical cases. 14 cytology cases lacked tumor cells on deeper levels. For 7 cases, surgical blocks were not retrievable. TRPS1 positivity for cytology and surgical cases were 52% and 47% respectively. In the malignant cohort, TRPS1 was positive in 21/32 (66%) cytology cases and 21/43 (56%) surgical cases. All cases of basal cell adenocarcinoma, carcinoma ex pleomorphic adenoma and salivary duct carcinoma were TRPS1 positive on cytology. All cases of adenoid cystic carcinoma and acinic cell carcinoma were TRPS1 positive on surgical resections. In the benign cohort, TRPS1 was positive in 2/12 (17%) cytology cases; however, none of the surgically resected benign cases showed reactivity (0/8). Cytology‐surgical correlation of TRPS1 staining was done in 37 cases. We found 21 concordant and 16 discordant cases. Discordance was highest in mucoepidermoid carcinoma.Conclusion: TRPS1 is not an entirely specific marker for breast carcinoma. TRPS1 positivity was noted in a substantial number of salivary gland malignant neoplasms. Cases demonstrating discordance in TRPS1 staining pattern on cytology‐surgical correlation warrant further exploration.
- 7 December 2024
- Published by Wiley in Diagnostic Cytopathology
- Vol. 53 (3) , 121-126
TRPS1 Immunohistochemistry in Salivary Gland Neoplasms: Analysis on Cytology Cell Blocks and Surgical Follow‐Up Correlation
Introduction: In this study we aim to analyze the TRPS1 immunostaining of salivary gland tumors (SGT) on cytology cell blocks and compare the staining pattern on subsequent surgical resections.Methods: Malignant SGTs, oncocytomas and basal cell adenomas diagnosed on fine needle aspiration were retrieved from 2019 to 2021 database. Cases with surgical follow‐up were selected. TRPS1 staining was performed on cytology cell blocks and surgical specimens. Scoring was interpreted by two pathologists independently.Results: Our cohort comprised of 58 cases: 45 malignant and 13 benign. TRPS1 scoring was interpreted for 44 cytology and 51 surgical cases. 14 cytology cases lacked tumor cells on deeper levels. For 7 cases, surgical blocks were not retrievable. TRPS1 positivity for cytology and surgical cases were 52% and 47% respectively. In the malignant cohort, TRPS1 was positive in 21/32 (66%) cytology cases and 21/43 (56%) surgical cases. All cases of basal cell adenocarcinoma, carcinoma ex pleomorphic adenoma and salivary duct carcinoma were TRPS1 positive on cytology. All cases of adenoid cystic carcinoma and acinic cell carcinoma were TRPS1 positive on surgical resections. In the benign cohort, TRPS1 was positive in 2/12 (17%) cytology cases; however, none of the surgically resected benign cases showed reactivity (0/8). Cytology‐surgical correlation of TRPS1 staining was done in 37 cases. We found 21 concordant and 16 discordant cases. Discordance was highest in mucoepidermoid carcinoma.Conclusion: TRPS1 is not an entirely specific marker for breast carcinoma. TRPS1 positivity was noted in a substantial number of salivary gland malignant neoplasms. Cases demonstrating discordance in TRPS1 staining pattern on cytology‐surgical correlation warrant further exploration.
- 25 November 2024
- Published by Wiley in Diagnostic Cytopathology
- Vol. 53 (3) , 102-110
Correlation of Cytologic Features With Molecular Testing of Indeterminate Oncocytic (Hürthle Cell) Thyroid Lesions
Introduction: Indeterminate oncocytic/Hürthle cell lesions on thyroid cytology are reflexed to molecular testing. This study aims to examine the cytologic characteristics of thyroid fine‐needle aspiration (FNA) smears with oncocytes classified as atypia of undetermined significance (AUS) with particular molecular patterns that can aid in determining a more conclusive Bethesda category upfront thus decreasing unnecessary testing and associated costs.Materials and Methods: Our pathology database was searched for thyroid FNAs with AUS for oncocyte predominance from 2019 to 2022. Sixty six cases that underwent ThyroSeq testing (33 positive and 33 negative) were selected. Two cytopathologists reviewed the smears for cellularity, colloid: cell ratio, artifacts, lymphocytes, microfollicles, and oncocytic nuclear atypia. Molecular results and surgical follow‐up were obtained through chart review. Statistical analysis was done using STATA16.1 (StataCorp LLC College Station, TX).Results: Among the 33 ThyroSeq‐positive cases, 20 had surgical follow‐up. Only 1 case was malignant. Hypercellularity, microfollicular architecture, and oncocytic atypia were associated with a higher incidence of molecular alterations. Five of 66 cases demonstrated microfollicles. Four of these had positive molecular findings, and one was negative. Twenty of 33 (61%) cases with positive molecular findings had no oncocytic nuclear atypia. Of the molecular positive cases with oncocytic atypia that underwent resection, seven of nine (78%) were neoplastic. RAS mutations were the most common finding detected in non‐neoplastic and neoplastic lesions.Conclusions: Microfollicles were infrequently seen in nodules with oncocytic predominance; however, those that had microfollicles had high incidence of positive molecular findings. Oncocytic nuclear atypia was present in all the resected neoplastic cases. NRAS and KRAS mutations were the most common molecular abnormalities detected.
- 25 November 2024
- Published by Wiley in Diagnostic Cytopathology
- Vol. 53 (3) , 102-110
Correlation of Cytologic Features With Molecular Testing of Indeterminate Oncocytic (Hürthle Cell) Thyroid Lesions
Introduction: Indeterminate oncocytic/Hürthle cell lesions on thyroid cytology are reflexed to molecular testing. This study aims to examine the cytologic characteristics of thyroid fine‐needle aspiration (FNA) smears with oncocytes classified as atypia of undetermined significance (AUS) with particular molecular patterns that can aid in determining a more conclusive Bethesda category upfront thus decreasing unnecessary testing and associated costs.Materials and Methods: Our pathology database was searched for thyroid FNAs with AUS for oncocyte predominance from 2019 to 2022. Sixty six cases that underwent ThyroSeq testing (33 positive and 33 negative) were selected. Two cytopathologists reviewed the smears for cellularity, colloid: cell ratio, artifacts, lymphocytes, microfollicles, and oncocytic nuclear atypia. Molecular results and surgical follow‐up were obtained through chart review. Statistical analysis was done using STATA16.1 (StataCorp LLC College Station, TX).Results: Among the 33 ThyroSeq‐positive cases, 20 had surgical follow‐up. Only 1 case was malignant. Hypercellularity, microfollicular architecture, and oncocytic atypia were associated with a higher incidence of molecular alterations. Five of 66 cases demonstrated microfollicles. Four of these had positive molecular findings, and one was negative. Twenty of 33 (61%) cases with positive molecular findings had no oncocytic nuclear atypia. Of the molecular positive cases with oncocytic atypia that underwent resection, seven of nine (78%) were neoplastic. RAS mutations were the most common finding detected in non‐neoplastic and neoplastic lesions.Conclusions: Microfollicles were infrequently seen in nodules with oncocytic predominance; however, those that had microfollicles had high incidence of positive molecular findings. Oncocytic nuclear atypia was present in all the resected neoplastic cases. NRAS and KRAS mutations were the most common molecular abnormalities detected.
- 20 August 2024
- Published by Wiley in Diagnostic Cytopathology
- Vol. 52 (12) , 756-762
Salivary Gland Neoplasm of Uncertain Malignant Potential (SUMP) (Milan IVB) and Its Subgroups: A Multi‐Institutional Analysis of Risk of Neoplasm and Malignancy
Objectives: Fine needle aspiration (FNA) plays a crucial role in their initial assessment of salivary gland neoplasms. In the Milan System for Reporting Salivary Gland Cytopathology (MSRSGC), the category of Salivary Gland Neoplasm of Uncertain Malignant Potential (SUMP) categorizes lesions with ambiguous features. This study aims to investigate the risk of neoplasm (RON) and risk of malignancy (ROM) within different subgroups of SUMP lesions using data from three large academic institutions.Methods: We analyzed salivary gland (FNA) cases from three academic institutions post‐MSRSGC implementation. Salivary gland FNA cases categorized as Milan IVB (SUMP) with subsequent surgical pathology follow‐up were analyzed. Cases were divided into basaloid, oncocytic, and clear cell SUMP subtypes, with RON and ROM assessed and compared.Results: Out of 1377 MSRSGC cases, 231 were SUMP (16.8%), with 101 subjected to surgical pathology follow‐up. The overall ROM for SUMP was 20.8%, with variations of 10% to 29.5% observed amongst institutions, but no significant difference was observed among three institutions (p = 0.15). Basaloid and oncocytic SUMP displayed 17.1% and 20.5% ROM, respectively, without significant disparity. However, all clear cell SUMP cases were malignant on surgical resection.Conclusions: This study highlights the variability in ROM for SUMP lesions and the significantly higher ROM in SUMP cases with clear cell features. These findings emphasize the importance of accurately subcategorizing SUMP lesions, particularly those with clear cell features, for appropriate clinical management.
- 20 August 2024
- Published by Wiley in Diagnostic Cytopathology
- Vol. 52 (12) , 756-762
Salivary Gland Neoplasm of Uncertain Malignant Potential (SUMP) (Milan IVB) and Its Subgroups: A Multi‐Institutional Analysis of Risk of Neoplasm and Malignancy
Objectives: Fine needle aspiration (FNA) plays a crucial role in their initial assessment of salivary gland neoplasms. In the Milan System for Reporting Salivary Gland Cytopathology (MSRSGC), the category of Salivary Gland Neoplasm of Uncertain Malignant Potential (SUMP) categorizes lesions with ambiguous features. This study aims to investigate the risk of neoplasm (RON) and risk of malignancy (ROM) within different subgroups of SUMP lesions using data from three large academic institutions.Methods: We analyzed salivary gland (FNA) cases from three academic institutions post‐MSRSGC implementation. Salivary gland FNA cases categorized as Milan IVB (SUMP) with subsequent surgical pathology follow‐up were analyzed. Cases were divided into basaloid, oncocytic, and clear cell SUMP subtypes, with RON and ROM assessed and compared.Results: Out of 1377 MSRSGC cases, 231 were SUMP (16.8%), with 101 subjected to surgical pathology follow‐up. The overall ROM for SUMP was 20.8%, with variations of 10% to 29.5% observed amongst institutions, but no significant difference was observed among three institutions (p = 0.15). Basaloid and oncocytic SUMP displayed 17.1% and 20.5% ROM, respectively, without significant disparity. However, all clear cell SUMP cases were malignant on surgical resection.Conclusions: This study highlights the variability in ROM for SUMP lesions and the significantly higher ROM in SUMP cases with clear cell features. These findings emphasize the importance of accurately subcategorizing SUMP lesions, particularly those with clear cell features, for appropriate clinical management.
- 25 May 2024
- Published by Wiley in Diagnostic Cytopathology
- Vol. 52 (9) , 499-504
TRPS1 function beyond breast: A retrospective immunohistochemical study on non‐breast cytology specimens
Introduction: Trichorhinophalangeal syndrome type 1 (TRPS1) has emerged as a reliable immunohistochemistry (IHC) marker for identifying breast origin in metastatic carcinomas. This study investigates the utility of TRPS1 IHC in non‐breast cytology specimens.Materials and Methods: A retrospective search of our pathology database for the year 2021 identified fluids (pleural and peritoneal) and liver, lung and bone fine needle aspirations (FNAs) with surgical follow‐up confirming non‐breast metastatic carcinomas. Cell blocks from cases with sufficient neoplastic cells underwent immunostaining using a rabbit polyclonal antibody against human TRPS1. Cases lacking tumor on deeper levels after the original work‐up were excluded from the study. Two pathologists independently interpreted the TRPS1 staining.Results: Of 136 cases assessed, 31 (22.79%) exhibited positive TRPS1 staining, while 105 (77.21%) were nonreactive. Positivity rates were observed in tumors of Mullerian cell origin, gastrointestinal tract (GIT), and lung origin at 28.85%, 25%, and 21.57%, respectively. Of the tumors of Mullerian cell origin 10 (66.67%) were serous carcinomas, 4 (26.67%) were endometrioid carcinomas, and one (6.67%) was a clear cell carcinoma. Lung tumors comprised seven (63.64%) squamous cell carcinomas and four (36.36%) adenocarcinomas, while the gastrointestinal tumors consisted of 14 (80%) adenocarcinomas and one (20%) squamous cell carcinoma.Conclusions: Although recognized as a sensitive marker for mammary carcinomas, TRPS1 immunostaining was also detected in Mullerian, lung, and GIT carcinomas. This highlights the significance of being cautious when depending solely on TRPS1 immunostaining to distinguish metastatic breast tumors.
- 25 May 2024
- Published by Wiley in Diagnostic Cytopathology
- Vol. 52 (9) , 499-504
TRPS1 function beyond breast: A retrospective immunohistochemical study on non‐breast cytology specimens
Introduction: Trichorhinophalangeal syndrome type 1 (TRPS1) has emerged as a reliable immunohistochemistry (IHC) marker for identifying breast origin in metastatic carcinomas. This study investigates the utility of TRPS1 IHC in non‐breast cytology specimens.Materials and Methods: A retrospective search of our pathology database for the year 2021 identified fluids (pleural and peritoneal) and liver, lung and bone fine needle aspirations (FNAs) with surgical follow‐up confirming non‐breast metastatic carcinomas. Cell blocks from cases with sufficient neoplastic cells underwent immunostaining using a rabbit polyclonal antibody against human TRPS1. Cases lacking tumor on deeper levels after the original work‐up were excluded from the study. Two pathologists independently interpreted the TRPS1 staining.Results: Of 136 cases assessed, 31 (22.79%) exhibited positive TRPS1 staining, while 105 (77.21%) were nonreactive. Positivity rates were observed in tumors of Mullerian cell origin, gastrointestinal tract (GIT), and lung origin at 28.85%, 25%, and 21.57%, respectively. Of the tumors of Mullerian cell origin 10 (66.67%) were serous carcinomas, 4 (26.67%) were endometrioid carcinomas, and one (6.67%) was a clear cell carcinoma. Lung tumors comprised seven (63.64%) squamous cell carcinomas and four (36.36%) adenocarcinomas, while the gastrointestinal tumors consisted of 14 (80%) adenocarcinomas and one (20%) squamous cell carcinoma.Conclusions: Although recognized as a sensitive marker for mammary carcinomas, TRPS1 immunostaining was also detected in Mullerian, lung, and GIT carcinomas. This highlights the significance of being cautious when depending solely on TRPS1 immunostaining to distinguish metastatic breast tumors.
- 7 February 2024
- Published by Wiley in Diagnostic Cytopathology
- Vol. 52 (8) , 413-423
COVID and cytopathology training: Impact and innovations
Graduate medical education and training in Cytopathology faced numerous unexpected challenges during the COVID-19 pandemic of 2020. It was caused by the SARS-Co-V2 coronavirus and transmitted by breathing droplets or aerosol particles containing the virus and less commonly by contact with infected surfaces and fomites. To mitigate the rapid spread of disease non-essential services were closed, surgical procedures were prioritized, and "social distancing" was implemented. These measures led to a marked decline in the volume of specimens, number of fine needle aspiration (FNA) and rapid on-site evaluation procedures performed. The trainees in Pathology were required to stay at home either entirely or partly during the early period of the pandemic. This led to re-designing of the cytopathology training program nationwide. Many innovative methods and protocols were put in place to overcome the challenges faced and adjustments made in creating the virtual training program in Cytopathology. On May 5th, 2023, the WHO declared that COVID-19 was no longer a global emergency. Regulations were lifted and healthcare services returned to pre-pandemic era. Graduate medical education and training returned to normal however many changes were incorporated into the training program moving forward. Herein the impacts and innovations that COVID-19 had on Cytopathology training are described.
- 7 February 2024
- Published by Wiley in Diagnostic Cytopathology
- Vol. 52 (8) , 413-423
COVID and cytopathology training: Impact and innovations
Graduate medical education and training in Cytopathology faced numerous unexpected challenges during the COVID-19 pandemic of 2020. It was caused by the SARS-Co-V2 coronavirus and transmitted by breathing droplets or aerosol particles containing the virus and less commonly by contact with infected surfaces and fomites. To mitigate the rapid spread of disease non-essential services were closed, surgical procedures were prioritized, and "social distancing" was implemented. These measures led to a marked decline in the volume of specimens, number of fine needle aspiration (FNA) and rapid on-site evaluation procedures performed. The trainees in Pathology were required to stay at home either entirely or partly during the early period of the pandemic. This led to re-designing of the cytopathology training program nationwide. Many innovative methods and protocols were put in place to overcome the challenges faced and adjustments made in creating the virtual training program in Cytopathology. On May 5th, 2023, the WHO declared that COVID-19 was no longer a global emergency. Regulations were lifted and healthcare services returned to pre-pandemic era. Graduate medical education and training returned to normal however many changes were incorporated into the training program moving forward. Herein the impacts and innovations that COVID-19 had on Cytopathology training are described.
- 19 October 2022
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 11 (6) , S81-S82
Approach to Out-of-Range Performance Indicators: A Quality Assurance Study
- 19 October 2022
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 11 (6) , S81-S82
Approach to Out-of-Range Performance Indicators: A Quality Assurance Study
- 19 October 2022
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 11 (6) , S59
Pancreatic Endoscopic Ultrasound-Guided FNA: Risk of Malignancy and Histologic Correlation of Atypical and Suspicious for Malignancy Categories
- 19 October 2022
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 11 (6) , S59
Pancreatic Endoscopic Ultrasound-Guided FNA: Risk of Malignancy and Histologic Correlation of Atypical and Suspicious for Malignancy Categories
- Open Access
- 13 July 2018
- Published by Scientific Scholar in Cytojournal
- Vol. 15 (1) , 16
Pleural effusion in a 7-year-old child - with unique cells
The Indian Journal of Cancer is an official publication of the Indian Cancer Society and Indian Society of Oncology.
- 13 July 2018
- Published by Scientific Scholar in Cytojournal
- Vol. 15 (1) , 16
Open AccessPleural effusion in a 7-year-old child - with unique cells
The Indian Journal of Cancer is an official publication of the Indian Cancer Society and Indian Society of Oncology.